Spotted another gem in the investor presentation which may have...

Spotted another gem in the investor presentation which may have been brushed over.



"progressing very well" and "high value of data collected" speaks volumes. The FDA only require a minimum dataset of 400 patients and we are now at 500 and counting. ResApp have continued to enrol and conduct trials because in my opinion, the accuracy numbers are increasing and greater variety of diseases are being diagnosed (we all know this is a 'self learning' algorithm).  

Lets also not underestimate how crucial having ResApp over the cloud is (SaaS API) - that means the app does not have to download every single cough spectrum and frequency to obtain a result rather only communicate with the server saving data and time.

All is well, even the backend is ready to launch.